- ►diabetesjournals.org SM Strowig, ML Avilés-Santa, P Raskin - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—HbA lc levels decreased in all groups, the lowest level occurring in
the insulin plus troglitazone group (insulin alone to 7.0%, insulin plus
metformin to 7.1%, and insulin plus troglitazone to 6.4%, P < 0.0001). The ... Cited by 61 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org SM Strowig, ML Avilés-Santa, P Raskin - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—HbA 1c levels decreased in both groups during dual therapy and
improved further during triple therapy (INS + MET 7.0 ± 0.8, INS + TGZ 6.2 ±
0.8, P < 0.0001; INS + MET, add TGZ 6.1 ± 0.4%, P < 0.001; INS + TGZ, add ... Cited by 49 - Related articles - BL Direct - All 5 versions
- Free from Publisher MG Wulffelé, A Kooy, P Lehert, D Bets, JC … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Metformin improves glycemic control in poorly
controlled type 2 diabetic patients. Its effect in type 2 diabetic patients who
are intensively treated with insulin has not been studied. A total of 390 ... Cited by 68 - Related articles - BL Direct - All 5 versions
- Free from Publisher NJ Furlong, SA Hulme, SV O'Brien, KJ Hardy - Diabetes care, 2002 - Am Diabetes Assoc RESULTS—Baseline age, diabetes duration, insulin requirement, weight, BMI,
FBG, and HbA 1c (Diabetes Control and Complications Trial–aligned assay,
normal range 4.6–6.2%) were similar. Glycemic control improved ( ... Cited by 26 - Related articles - BL Direct - All 7 versions
- ►annals.org [PDF] L Aviles-Santa, J Sinding, P Raskin - Annals of Internal Medicine, 1999 - Am Coll Physicians Larissa Avilés-Santa, MD; Joyce Sinding, MSN, RN; and Philip Raskin, MD ...
Background: Patients with type 2 diabetes are often obese and require large
doses of insulin to achieve glyce- mic control. Weight gain often ... Cited by 168 - Related articles - BL Direct - All 5 versions
HH Ponssen, JWF Elte, P Lehert, JP Schouten … - Clinical therapeutics, 2000 - Elsevier Thirty-one patients (24 women, 7 men; mean age, 61.8 years; mean body mass index
[BMI], 28.0 kg/m 2 ) were enrolled in this randomized, double-blind, 2-way,
crossover, placebo-controlled study. Patients with type 2 diabetes who were ... Cited by 27 - Related articles - BL Direct - All 5 versions
A Fritsche, RM Schmülling, HU Häring, M … - Acta Diabetologica, 2000 - Springer Abstract Unlike other pharmacological therapies used in obese type 2 diabetic
patients, metformin has been shown to improve glycemic control with lower
insulin levels and not to involve weight gain. We therefore examined the ... Cited by 23 - Related articles - BL Direct - All 4 versions
MN Feinglos, CR Thacker, B Lobaugh, DD … - Diabetes research and clinical practice, 1998 - Elsevier Numerous studies exist that report the efficacy of combined insulin and
sulfonylurea therapy [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
and the American Diabetes Association guidelines have suggested that ... Cited by 18 - Related articles - All 6 versions
- ►diabetesjournals.org [PDF] MC Riddle, J Schneider - Diabetes Care, 1998 - Am Diabetes Assoc F rom the Oregon Health Sciences University (MCR), Portland, Oregon; and Hoechst
Marion Roussel Phar- maceuticals (JS), Somerville, New Jersey. A dd ress
correspondence and reprint requests to Matthew C. Riddle, MD, Section of ... Cited by 83 - Related articles - BL Direct - All 7 versions
SM Strowig, P Raskin - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com The biguanide, metformin, sensitizes the liver to the effect of insulin,
suppressing hepatic glucose output. Thiazolidinediones such as rosiglitazone and
pioglitazone enhance insulin-mediated glucose disposal, leading to reduced ... Cited by 20 - Related articles - BL Direct - All 5 versions
